Liver Function Tests for Terbinafine Monitoring
Measure serum transaminases (ALT and AST) before starting terbinafine, with periodic monitoring recommended during treatment, particularly at 4-6 weeks after initiation. 1
Baseline Testing Required
The FDA drug label explicitly states that measurement of serum transaminases (ALT and AST) is advised for all patients before taking terbinafine 1. This baseline assessment is critical because hepatotoxicity can occur in patients both with and without pre-existing liver disease.
High-Risk Patients Requiring Baseline Testing
Baseline liver function tests AND complete blood count are specifically recommended for patients with: 2
- History of heavy alcohol consumption
- History of hepatitis
- Hematological abnormalities
- Pediatric patients (as terbinafine is unlicensed for children)
Periodic Monitoring During Treatment
Periodic monitoring of liver function tests is recommended during terbinafine therapy 1. While the exact timing isn't rigidly defined in guidelines, the evidence suggests:
- Most cases of drug-induced liver injury occur between 4-6 weeks after starting treatment 3, 4
- The mean duration until symptom onset is approximately 30 days (range 5-84 days) 4
- Monitoring at 4-6 weeks is commonly practiced, particularly for patients on treatment exceeding 6 weeks 3
Which Specific Tests to Order
The essential tests are:
- ALT (alanine aminotransferase)
- AST (aspartate aminotransferase)
Additional tests to consider:
- Alkaline phosphatase (ALP) - as terbinafine can cause cholestatic injury 5, 3, 6
- Total bilirubin - particularly important as jaundice is the most common presenting symptom 4
- Complete blood count - especially in high-risk patients or if treatment exceeds 6 weeks 1
Critical Clinical Context
The Monitoring Controversy
A 2017 systematic review challenges routine laboratory monitoring, finding that no asymptomatic patients were identified through laboratory screening 4. All patients with drug-induced liver injury were symptomatic, typically presenting with jaundice, abdominal pain, malaise, or severe pruritus before laboratory abnormalities were detected.
However, the FDA label and British Association of Dermatologists guidelines still recommend baseline and periodic monitoring 2, 1, representing the standard of care despite this evidence.
When to Stop Terbinafine Immediately
Discontinue terbinafine immediately if: 1
- Elevation of liver function tests occurs
- Patient develops symptoms: persistent nausea, anorexia, fatigue, vomiting, right upper abdominal pain, jaundice, dark urine, or pale stools
Important Pitfalls
- Isolated alkaline phosphatase elevation can occur without other LFT abnormalities - don't dismiss this as non-hepatic 6
- Terbinafine causes both hepatocellular injury (elevated ALT/AST) and cholestatic injury (elevated ALP) 5, 3
- The AST:ALT ratio in affected patients averages around 1.5, suggesting mixed injury patterns 4
- Recovery typically occurs within 11-15 months after drug cessation, though severe cases have been reported 5
Patient Education is Critical
Patients must be instructed to report symptoms immediately and discontinue the drug if they experience warning signs of hepatotoxicity 1. This symptom-based surveillance may be more effective than laboratory monitoring alone 4.